atai Life Sciences pipeline update and development progress of BPL-003, VLS-01 and EMP-01 programs

atai Life Sciences is a clinical-stage biopharmaceutical company focused on developing innovative mental health treatments, primarily utilizing psychedelic compounds. Our pipeline targets conditions with significant unmet needs like treatment-resistant depression (TRD), social anxiety disorder (SAD), and alcohol use disorder (AUD).Key candidates include BPL-003 (intranasal 5-MeO-DMT), which has shown rapid and durable antidepressant effects in Phase 2a studies for TRD, with a Phase 2b study currently underway and topline results expected mid-2025. VLS-01 (buccal film DMT) is in Phase 2 for TRD, targeting a short in-clinic treatment time and EMP-01 (oral R-MDMA) is in a Phase 2 study for SAD.